Cargando…

Engineered calprotectin-sensing probiotics for IBD surveillance in humans

Inflammatory bowel disease (IBD) is a spectrum of autoimmune diseases affecting the gastrointestinal tract characterized by a relapsing and remitting course of gut mucosal inflammation. Disease flares can be difficult to predict, and the current practice of IBD disease activity surveillance through...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Jonathan Y., Hepler, Chelsea, Tran, Peter, Waldeck, Nathan J., Bass, Joseph, Prindle, Arthur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Physical Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410751/ https://www.ncbi.nlm.nih.gov/pubmed/37523538 http://dx.doi.org/10.1073/pnas.2221121120

Ejemplares similares

Calprotectin instability may lead to undertreatment in children with IBD
por: Haisma, Sjoukje-Marije, et al.
Publicado: (2020)

What calprotectin cut-offs should apply for IBD in general practice?
por: Landis, Darryl, et al.
Publicado: (2016)

Circadian mechanisms in adipose tissue bioenergetics and plasticity
por: Hepler, Chelsea, et al.
Publicado: (2023)

Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico
por: Maldonado-Arriaga, Brenda, et al.
Publicado: (2021)

Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results
por: Kyle, Barry D, et al.
Publicado: (2020)

Can 2 Different Fecal Calprotectin Assays be Used Interchangeably in IBD Treatment?
por: van Wassenaer, Elsa A., et al.
Publicado: (2022)

Factors Associated With Fecal Calprotectin Sample Collection Compliance: An IBD Center Quality Improvement Project
por: Fenton, David, et al.
Publicado: (2022)

Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?
por: Dhaliwal, A, et al.
Publicado: (2015)

High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score
por: Bodelier, Alexander G. L., et al.
Publicado: (2016)

Fecal calprotectin Level in patients with IBD and noninflammatory disease of colon: a study in Babol, Northern, Iran
por: Sharbatdaran, Majid, et al.
Publicado: (2018)

Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients
por: Vicente-Steijn, R., et al.
Publicado: (2020)

Neurogenetic basis for circadian regulation of metabolism by the hypothalamus
por: Cedernaes, Jonathan, et al.
Publicado: (2019)

Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD
por: Martyniak, Adrian, et al.
Publicado: (2021)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation
por: Fu, Yu, et al.
Publicado: (2017)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Clinical Utility And Diagnostic Accuracy of Faecal Calprotectin For IBD At First Presentation To Gastroenterology Services In Adults Aged 16–50 Years
por: Kennedy, Nicholas A., et al.
Publicado: (2015)

Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility
por: Scaldaferri, Franco, et al.
Publicado: (2013)

COVID-19: Colorectal cancer endoscopic surveillance in IBD
por: Din, Shahida, et al.
Publicado: (2021)

The Role of Fecal Calprotectin in Investigating Inflammatory Bowel Diseases
por: Erbayrak, Mustafa, et al.
Publicado: (2009)

Calprotectin: from biomarker to biological function
por: Jukic, Almina, et al.
Publicado: (2021)

The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)—A Critical Review
por: Jakubczyk, Dominika, et al.
Publicado: (2020)

Tannins amount determines whether tannase-containing bacteria are probiotic or pathogenic in IBD
por: He, Qiuyue, et al.
Publicado: (2023)

COVID-19 and immunomodulation in IBD
por: Neurath, Markus F
Publicado: (2020)

Reduced Fecal Calprotectin and Inflammation in a Murine Model of Atopic Dermatitis Following Probiotic Treatment
por: Kim, Myoung-Ju, et al.
Publicado: (2020)

Bile Salt Hydrolase-Competent Probiotics in the Management of IBD: Unlocking the “Bile Acid Code”
por: Gadaleta, Raffaella Maria, et al.
Publicado: (2022)

The Role of Combining Probiotics in Preventing and Controlling Inflammation: A Focus on the Anti-Inflammatory and Immunomodulatory Effects of Probiotics in an In Vitro Model of IBD
por: Aghamohammad, Shadi, et al.
Publicado: (2022)

Detection of Calprotectin and Apoptotic Activity in the Colon of Marmosets with Chronic Diarrhea
por: NAKASHIMA, Erika, et al.
Publicado: (2013)

MicroRNAs: new players in IBD
por: Kalla, R, et al.
Publicado: (2015)

Fecal calprotectin and RT-PCR from both nasopharyngeal swab and stool samples prior to treatment decision in IBD patients during CoVID-19 outbreak.
por: Younes, Cherradi
Publicado: (2020)

Engineered probiotics
por: Ma, Junheng, et al.
Publicado: (2022)

Calprotectin in Cystic Fibrosis
por: Rumman, Nisreen, et al.
Publicado: (2014)

Calprotectin in Lung Diseases
por: Kotsiou, Ourania S., et al.
Publicado: (2021)

Lactococcus lactis, A Tool for the Delivery of Therapeutic Proteins Treatment of IBD
por: Steidler, Lothar
Publicado: (2001)

Sensing array of radically coupled genetic biopixels
por: Prindle, Arthur, et al.
Publicado: (2011)

Impact of IBD-Associated Dysbiosis on Bacterial Quorum Sensing Mediated by Acyl-Homoserine Lactone in Human Gut Microbiota
por: Grellier, Nathan, et al.
Publicado: (2022)

WNT-Pathway Activation in IBD-Associated Colorectal Carcinogenesis: Potential Biomarkers for Colonic Surveillance
por: Claessen, Marian M. H., et al.
Publicado: (2010)

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis
por: Jarlborg, Matthias, et al.
Publicado: (2020)

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists
por: Bilal, Mohammad, et al.
Publicado: (2017)

Stool Calprotectin in Necrotizing Enterocolitis
por: Albanna, Ehab AM, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7c1peibnb5cov75v4pc4gtauqo